Citations

Clear

3942 citation(s) found for "To, Van".

Integrated human-machine interface for closed-loop stimulation using implanted and wearable devices
Sladky, Vladimir , McQuown, Kevin, Brinkmann, Benjamin H. , Miller, Kai J. , Brinkmann, Benjamin H , Křemen, Václav , Mívalt, Filip , Gompel, Jamie J. Van , Denison, Timothy , Worrell, Gregory A.

Mayo Clinic

2022 IEEE International Conference on Systems, Man, and Cybernetics (SMC) | November 18, 2022 | Volume: No volume available | Issue: No issue available | Pages: 1730-1735

10.1109/smc53654.2022.9945203 Get It

Integrating Mechanisms in Thrombotic Peripheral Arterial Disease
Nagy, Magdolna , Meijden, Paola E. J. van der , Glunz, Julia, Schurgers, Leon J. , Lutgens, Esther, Cate, Hugo Ten , Heitmeier, Stefan , Spronk, Henri M.H. , van der Meijden, Paola E J , Schurgers, Leon , Ten Cate, Hugo

Mayo Clinic

Pharmaceuticals | November 18, 2022 | Volume: 15 | Issue: 11 | Pages: 1428

10.3390/ph15111428 | PMID 36422558 Get It

Peripheral arterial disease (PAD), a manifestation of systemic atherosclerosis, is underdiagnosed in the general population. Despite the extensive research performed to unravel its pathophysiology, inadequate knowledge exists, thus preventing the development of new treatments. This review aims to highlight the essential elements of atherosclerosis contributing to the pathophysiology of PAD. Furthermore, emphasis will be placed on the role of thrombo-inflammation, with particular focus on platelet and coagulation activation as well as cell–cell interactions. Additional insight will be then discussed to reveal the contribution of hypercoagulability to the development of vascular diseases such as PAD. Lastly, the current antithrombotic treatments will be discussed, and light will be shed on promising new targets aiming to aid the development of new treatments.
Neurotization during Breast Reconstruction
Morris, Bryn E., Spronsen, Nicole R. Van, Shrout, Max A., Teven, Chad M. , Rebecca, Alanna M. , Van Spronsen, Nicole R, Spronsen, Nicole Van

Mayo Clinic

Plastic and Reconstructive Surgery - Global Open | November 16, 2022 | Volume: 10 | Issue: 11 | Pages: e4591

10.1097/gox.0000000000004591 | PMID 36405045 Get It

Development of a Clinical Prediction Model for Diabetes in Chronic Pancreatitis: The PREDICT3c Study
Hart, Phil A. , Li, Liang , Yang, Yunlong, Chang, Eleanor, Bellin, Melena D. , Fisher, William E., Fogel, Evan L. , Forsmark, Christopher E., Park, Walter G. , Vege, Santhi Swaroop , Andersen, Dana K. , Conwell, Darwin L. , Yadav, Dhiraj , Goodarzi, Mark O. , Bellin, Melena D , Yadav, Dhiraj , Goodarzi, Mark O , Jeon, Christie Y. , Van Den Eeden, Stephen K , Serrano, José , Whitcomb, David C. , Conwell, Darwin L.

Mayo Clinic

Diabetes Care | November 16, 2022 | Volume: 46 | Issue: 1 | Pages: 46-55

10.2337/dc22-1414 | PMID 36382801 Get It

OBJECTIVE Diabetes that arises from chronic pancreatitis (CP) is associated with increased morbidity and mortality. Methods to predict which patients with CP are at greatest risk for diabetes are urgently needed. We aimed to examine independent risk factors for diabetes in a large cohort of patients with CP. RESEARCH DESIGN AND METHODS This cross-sectional study comprised 645 individuals with CP enrolled in the PROCEED study, of whom 276 had diabetes. We conducted univariable and multivariable regression analyses of potential risk factors for diabetes. Model performance was assessed by area under the receiver operating characteristic curve (AUROC) analysis, and accuracy was evaluated by cross validation. Exploratory analyses were stratified according to the timing of development of diabetes relative to the diagnosis of pancreatitis. RESULTS Independent correlates of diabetes in CP included risk factors for type 2 diabetes (older age, overweight/obese status, male sex, non-White race, tobacco use) as well as pancreatic disease–related factors (history of acute pancreatitis complications, nonalcoholic etiology of CP, exocrine pancreatic dysfunction, pancreatic calcification, pancreatic atrophy) (AUROC 0.745). Type 2 diabetes risk factors were predominant for diabetes occurring before pancreatitis, and pancreatic disease–related factors were predominant for diabetes occurring after pancreatitis. CONCLUSIONS Multiple factors are associated with diabetes in CP, including canonical risk factors for type 2 diabetes and features associated with pancreatitis severity. This study lays the groundwork for the future development of models integrating clinical and nonclinical data to identify patients with CP at risk for diabetes and identifies modifiable risk factors (obesity, smoking) on which to focus for diabetes prevention.
Association of Physical Activity With Neurofilament Light Chain Trajectories in Autosomal Dominant Frontotemporal Lobar Degeneration Variant Carriers
Casaletto, Kaitlin B. , Kornack, John, VandeBunte, Anna M. , Staffaroni, Adam S., Lee, Shannon, Heuer, Hilary W. , Forsberg, Leah K. , Ramos, Eliana Marisa , Kramer, Joel H. , Yaffe, Kristine , Petrucelli, Leonard , Boxer, Adam L. , Rosen, Howard J. , Apostolova, Liana G. , Barmada, Sami J. , Bordelon, Yvette , Brushaber, Danielle , Coppola, Giovanni, Darby, Ryan, Domoto-Reilly, Kimiko, Faber, Kelley, Fagan, Anne M. , Fields, Julie A. , Geschwind, Daniel H. , Ghoshal, Nupur , Gavrilova, Ralitza, Graff-Radford, Jonathon, Graff‐Radford, Neill R. , Grant, Ian , Grossman, Murray, Hall, Matthew , Huey, Edward D. , Kauer, Daniel, Kornak, John , Lago, Argentina Lario , Lee, Suzee, Ljubenkov, Peter A. , Lucente, Diana E., Mackenzie, Ian R. , Masdeux, Joseph C., McGinnis, Scott, Mendez, Mario F. , Mester, Carly , Onyike, Chiadi U. , Pascual, María Belén, Rademakers, Rosa , Rao, Meghana , Rascovsky, Katya, Rankin, Katherine P. , Ritter, Aaron, Savica, Rodolfo , Syrjanen, Jeremy A. , Staffaroni, Adam M. , Taylor, Jack C. , Weıntraub, Sandra , Damme, Philip Van , Van Damme, Philip , Barmada, Sami , Paolillo, Emily W. , Rojas, Julio C. , Miller, Bruce L. , Boeve, Bradley F. , Gendron, Tania F. , Appleby, Brian S. , Botha, Hugo , Bozoki, Andrea C , Clark, David , Coppola, Giovanni, Dickerson, Bradford Clark , Dickson, Dennis W. , Domoto‐Reilly, Kimiko , Foroud, Tatiana , Goldman, Jill , Galasko, Douglas , Huang, Eric J. , Hsiung, Ging‐Yuek Robin , Irwin, David J. , Kantarci, Kejal , Kerwin, Diana , Knopman, David S. , Kremers, Walter K. , Lapid, Maria I. , Léger, Gabriel C. , Litvan, Irene , Pressman, Peter, Ramanan, Vijay K. , Seeley, William W. , Tartaglia, Maria Carmela , VandeVrede, Lawren , Wong, Bonnie

Mayo Clinic

JAMA Neurology | November 14, 2022 | Volume: 80 | Issue: 1 | Pages: 82

10.1001/jamaneurol.2022.4178 | PMID 36374516 Get It

ImportancePhysical activity is associated with cognitive health, even in autosomal dominant forms of dementia. Higher physical activity is associated with slowed cognitive and functional declines over time in adults carrying autosomal dominant variants for frontotemporal lobar degeneration (FTLD), but whether axonal degeneration is a potential neuroprotective target of physical activity in individuals with FTLD is unknown.ObjectiveTo examine the association between physical activity and longitudinal neurofilament light chain (NfL) trajectories in individuals with autosomal dominant forms of FTLD.Design, Setting, and ParticipantsThis cohort study included individuals from the ALLFTD Consortium, which recruited patients from sites in the US and Canada. Symptomatic and asymptomatic adults with pathogenic variants in one of 3 common genes associated with FTLD (GRN, C9orf72, or MAPT) who reported baseline physical activity levels and completed annual blood draws were assessed annually for up to 4 years. Genotype, clinical measures, and blood draws were collected between December 2014 and June 2019; data were analyzed from August 2021 to January 2022. Associations between reported baseline physical activity and longitudinal plasma NfL changes were assessed using generalized linear mixed-effects models adjusting for baseline age, sex, education, functional severity, and motor symptoms.ExposuresBaseline physical activity levels reported via the Physical Activity Scale for the Elderly. To estimate effect sizes, marginal means were calculated at 3 levels of physical activity: 1 SD above the mean represented high physical activity, 0 SD represented average physical activity, and 1 SD below the mean represented low physical activity.Main Outcomes and MeasuresAnnual plasma NfL concentrations were measured with single-molecule array technology.ResultsOf 160 included FTLD variant carriers, 84 (52.5%) were female, and the mean (SD) age was 50.7 (14.7) years. A total of 51 (31.8%) were symptomatic, and 77 carried the C9orf72 variant; 39, GRN variant; and 44, MAPT variant. Higher baseline physical activity was associated with slower NfL trajectories over time. On average, NfL increased 45.8% (95% CI, 22.5 to 73.7) over 4 years in variant carriers. Variant carriers with high physical activity demonstrated 14.0% (95% CI, −22.7 to −4.3) slower NfL increases compared with those with average physical activity and 30% (95% CI, −52.2 to −8.8) slower NfL increases compared with those with low physical activity. Within genotype, C9orf72 and MAPT carriers with high physical activity evidenced 18% to 21% (95% CI, −43.4 to −7.2) attenuation in NfL, while the association between physical activity and NfL trajectory was not statistically significant in GRN carriers. Activities associated with higher cardiorespiratory and cognitive demands (sports, housework, and yardwork) were most strongly correlated with slower NfL trajectories (vs walking and strength training).Conclusions and RelevanceIn this study, higher reported physical activity was associated with slower progression of an axonal degeneration marker in individuals with autosomal dominant FTLD. Physical activity may serve as a primary prevention target in FTLD.
PATH-36. GENOMIC MARKERS OF RECURRENCE RISK IN ATYPICAL MENINGIOMA FOLLOWING GROSS TOTAL RESECTION
Weiskittel, Taylor M. , Jenkins, Sarah M. , Dasari, Surendra , Uhm, Joon H. , Kipp, Benjamin R. , Sukov, William R. , Vaubel, Rachael A. , Kumar, Rahul , Lachance, Daniel Honore , Brown, Paul, Gompel, Jamie J. Van , Giannini, Caterina , Johnson, Derek R. , Raghunathan, Aditya

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii158-vii158

10.1093/neuonc/noac209.609 Get It

Abstract Atypical meningiomas (CNS WHO grade 2) show an intermediate risk of recurrence/progression, and molecular parameters informing management following gross total resection (GTR) remain to be established. We performed comprehensive genomic analysis in 63 patients who underwent GTR of an atypical meningioma. Median age was 59.8 years, 41 patients (65.1%) were female, and 8/62 patients (12.9%) underwent radiation therapy following resection. Follow-up was available for all patients (median 10 years), with recurrence/progression in 17 (5-year PFS: 84.2%; 10-year PFS: 71.0%). Tumors were evaluated by next generation sequencing (n=61), chromosomal microarray (n=63), DNA methylation profiling (n=62), and H3K27me3 immunohistochemistry (n=62). Next generation sequencing using a CLIA-certified 50-gene Neuro-Oncology specific panel identified pathogenic alterations in NF2 (n=31; 50.8%), SMARCB1 (n=5; 8.2%), AKT1 (n=2; 3.3%), TERT (n=1, 1.6%), SMO (n=1), SUFU (n=1), TP53 (n=1), and PTEN (n=1). There was trend toward decreased PFS in patients with NF2 alterations (p=0.078) which was not statistically significant. Copy number variants (CNVs) were identified using OncoScan (ThermoFisher). The most frequent CNVs were loss -22 (n=45; 71.4%), -1p (n=30, 47.6%), -14 (n=21, 33.3%), -6q (n=18, 28.6%), -10q (n=15, 23.8%), -X (n=13, 20.6%), and -18 (n=11, 17.4%). CNVs associated with decreased PFS included -1p (p=0.015), -7p (p=0.007), -10q (p=0.0007), and -18 (p=0.0376). DNA methylation profiling was performed using the Illumina MethylationEPIC array (n=62) and evaluated using the DKFZ classifier (v12.3). Based on the highest score, tumors matched to benign (n=32; 51.6%) or intermediate (n=29; 46.7%) meningioma subclasses or showed non-contributory profiles (n=1; 1.6%). Methylation class (benign vs. intermediate) showed no association with PFS (p=0.96). H3K27 trimethylation (H3K27me3) was unequivocally lost in 4 (6.5%) tumors, which was insufficient for PFS analysis. Overall, our study supports CNV profiling of atypical meningiomas following GTR, which can be implemented using existing, clinically validated technologies. Molecular predictors could guide use of radiotherapy in these patients.
NIMG-42. DURABLE OVERALL RESPONSE RATE (ORR) TARGETS FOR RECURRENT GLIOBLASTOMA (RGBM) CLINICAL TRIALS BASED ON THE HISTORIC ASSOCIATION BETWEEN ORR AND MEDIAN OVERALL SURVIVAL (MOS)
Wen, Patrick Y. , Chang, Susan M. , Vogelbaum, Michael A. , Li, Gang, Lassman, Andrew B. , Gilbert, Mark, Ellingson, Benjamin M. , Wen, Patrick Yung , Bent, Martin J. van den , Li, Shanpeng , Kim, Jiyoon , Youssef, Gilbert , Wick, Wolfgang , Groot, John de , Weller, Michael , Galanis, Evanthia , Cloughesy, Timothy F.

Mayo Clinic

Neuro-Oncology | November 14, 2022 | Volume: 24 | Issue: Supplement_7 | Pages: vii172-vii173

10.1093/neuonc/noac209.660 Get It

Abstract Durable overall response rate (ORR) remains a meaningful endpoint in recurrent GBM; however, the target ORR for single arm recurrent GBM trials has not been based on historic information or tied to patient outcomes. The current study reviewed past trials in recurrent GBM in order to judiciously define target ORRs for use in recurrent GBM trials. After reviewing 69 treatment arms comprising 4,971 patients, ORR was 6.1%[95% CI 4.23; 8.76%] for cytotoxic chemotherapies (ORR=7.59% for CCNU, 7.57% for TMZ, 0.64% for CPT-11, and 5.32% for other agents), 3.37% for biologic agents, 7.97% for immunotherapies (select trials), and 26.8% for anti-angiogenic agents. ORRs were significantly correlated with median overall survival (mOS) across chemotherapy (R2=0.4078, P< 0.0001), biologics (R2=0.4003, P=0.0003), and immunotherapy trials (R2=0.8994, P< 0.0001), but not anti-angiogenic agents (R2=0, P=0.8937). Pooling data from chemotherapy, biologics, and immunotherapy trials, a meta-analysis indicated a strong correlation between ORR and mOS (R2=0.3164, P< 0.0001; mOS[weeks]=0.6xORR+28.9), suggesting an ORR >20% results in an mOS of > 40.9 weeks, which is double the survival estimate of a treatment with ORR=0% and ≥ 2 months longer than treatments with ORR=5%. Assuming an ineffective therapy (control) has ORR=5%, a trial of 32 patients with a target ORR=20% leads to the 95% confidence interval higher than the control group. We conclude that single arm phase II studies in recurrent GBM with ≥ 32 patients should have a target ORR ≥ 20%. This was associated with a median OS of approximately 1 year. Importantly, durability of response should also be considered and was not assessed in the current meta-analysis.
Palliative Care Utilization Among Hospitalized Patients With Common Chronic Conditions in the United States
Rashid, Muhammad , Warriach, Haider J, Lawson, Claire , Spall, Harriette G.C. Van , Khan, M Shahzab, Mohamed, Mohamed O. , Shoaib, Ahmad , Diwan, Masroor, Gosh, Raktim, Bhatt, Deepak L. , Mamas, Mamas A. , Van Spall, Harriette G C , Mamas, Mamas , Bhatt, Deepak L , Mohamed, Mohamed O , Alkhouli, Mohamad , Khan, Safi U. , Khan, Muhammad Zia

Mayo Clinic

Journal of Palliative Care | November 14, 2022 | Volume: 41 | Issue: 1 | Pages: 28-40

10.1177/08258597221136733 | PMID 36373247 Get It

Objective: Limited data exist around the receipt of palliative care (PC) in patients hospitalized with common chronic conditions. We studied the independent predictors, temporal trends in rates of PC utilization in patients hospitalized with acute exacerbation of common chronic diseases. Methods: Population-based cohort study of all hospitalizations with an acute exacerbation of heart disease (HD), cerebrovascular accident (CVA), cancer (CA), and chronic lower respiratory disease (CLRD). Patients aged ≥18 years or older between January 1, 2004, and December 31, 2017, referred for inpatient PC were extracted from the National Inpatient Sample. Poisson regression analyses were used to estimate temporal trends. Results: Between 2004 and 2017, of 91,877,531 hospitalizations, 55.2%, 13.9%, 17.2%, and 13.8% hospitalizations were related to HD, CVA, CA, and CLRD, respectively. There was a temporal increase in the uptake of PC across all disease groups. Age-adjusted estimated rates of PC per 100,000 hospitalizations/year were highest for CA (2308 (95% CI 2249–2366) to 10,794 (95% CI 10,652–10,936)), whereas the CLRD cohort had the lowest rates of PC referrals (255 (95% CI 231–278) to 1882 (95% CI 1821–1943)) between 2004 and 2017, respectively. In the subgroup analysis of patients who died during hospitalization, the CVA group had the highest uptake of PC per 100,000 hospitalizations/year (4979 (95% CI 4918–5040)) followed by CA (4241 (95% CI 4189–4292)), HD (3250 (95% CI 3211–3289)) and CLRD (3248 (95% CI 3162–3405)). Conclusion: PC service utilization is increasing but remains disparate, particularly in patients that die during hospital admission from common chronic conditions. These findings highlight the need to develop a multidisciplinary, patient-centered approach to improve access to PC services in these patients.
Long-term Outcomes following Operative Management of Pediatric Scapholunate Ligament Injuries
Kampen, Robert J. van , Baltzer, Heather L. , Moran, Steven L. , van Kampen, Robert J , Fox, Paige M, Baltzer, Heather L , Fox, Paige M.

Mayo Clinic

Journal of Wrist Surgery | November 9, 2022 | Volume: 12 | Issue: 01 | Pages: 056-062

10.1055/s-0042-1757779 | PMID 36644723 Get It

Abstract Background Scapholunate (SL) ligament injuries are rarely diagnosed in children. This study reports the outcomes of surgically treated SL ligament injuries in patients younger than 18 years. Methods A retrospective review was performed on 20 pediatric patients with SL ligament injuries. Records were reviewed for preoperative and postoperative radiographic data, intraoperative findings, classifications of interosseous ligament injury, and postoperative course. Results Thirteen girls and seven boys sustained SL injuries requiring operative intervention and were followed for an average of 26 months. Magnetic resonance imaging (MRI) was performed in 15 patients, which revealed an SL tear in 7 patients. Arthroscopically, SL injuries were classified as Geissler grade III in 12 patients and grade IV in 5 patients. Based on the Mayo Wrist Score, nine patients had excellent or good results, while six demonstrated fair results. The mean wrist flexion–extension arc was 109 degrees, while the mean grip strength was 82% of the unaffected side. Patients treated >1 year following injury had significantly decreased grip strength and Mayo Wrist Score. Conclusion In this study, worse results were seen in children with a protracted course prior to treatment of an SL injury. A high index of suspicion is necessary to detect an SL injury in the younger age group and should be in the differential for those with persistent dorsal wrist pain, tenderness over the dorsal SL joint, and/or positive Watson's test. MRI may assist in diagnosis but is not definitive to rule out injury. Arthroscopy is valuable to determine the extent of injury.